79 results
Keyword NovoRapid Penfill Remove keyword
-
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 May 2022
European Medicines Agency, Amsterdam, the Netherlands, from 02/05/2022 to 05/05/2022, Last updated: 06/02/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 February 2023
European Medicines Agency, Amsterdam, the Netherlands, from 20/02/2023 to 23/02/2023, Last updated: 24/04/2023 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 31/05/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 7-10 November 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/11/2022 to 10/11/2022, Last updated: 10/01/2023 -
List item
Public data from Article 57 database
Last updated: 17/10/2022 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/05/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2021
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2021 to 22/04/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 March 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/03/2021 to 25/03/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 10-13 October 2022
European Medicines Agency, Amsterdam, the Netherlands, from 10/10/2022 to 13/10/2022, Last updated: 23/11/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 21/06/2021 to 24/06/2021, Last updated: 07/12/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 03/05/2021 to 06/05/2021, Last updated: 27/02/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-29 January 2021
Virtual meeting, from 25/01/2021 to 29/01/2021, Last updated: 04/03/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 May 2017
European Medicines Agency, London, UK, from 02/05/2017 to 05/05/2017, Last updated: 13/03/2014aspart – NOVOMIX (CAP), NOVORAPID (CAP); insulin bovine (NAP … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 November 2017
European Medicines Agency, London, UK, from 27/11/2017 to 30/11/2017, Last updated: 27/11/2017 -
List item
Newsletters (updated)
Last updated: 30/05/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 11-14 April 2016
European Medicines Agency, London, UK, from 11/04/2016 to 14/04/2016, Last updated: 13/03/2014 -
List item
Sampling and testing
Last updated: 28/03/2019 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 September 2016
European Medicines Agency, London, UK, from 12/09/2016 to 15/09/2016, Last updated: 06/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 April 2018
European Medicines Agency, London, UK, from 09/04/2018 to 12/04/2018, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 25-29 September 2017
European Medicines Agency, London, UK, from 25/09/2017 to 29/09/2017, Last updated: 06/09/2017 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 October 2020
Virtual meeting, from 12/10/2020 to 15/10/2020, Last updated: 16/10/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 15-18 May 2017
European Medicines Agency, London, UK, from 15/05/2017 to 18/05/2017, Last updated: 06/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 February 2013
European Medicines Agency, London, UK, from 04/02/2013 to 07/02/2013, Last updated: 02/06/2012 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 April 2023
PRAC, Last updated: 14/04/2023 -
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use14-17 February 2005
CHMP, Last updated: 17/02/2005Union on 1 June 2004. NovoRapid (insulin aspart), Novo Nordisk … children of 2-6 years of age. Novorapid was authorised in the European …